Advanced search
1 file | 4.35 MB Add to list

Ileal immune tonus is a prognosis marker of proximal colon cancer in mice and patients

(2021) CELL DEATH AND DIFFERENTIATION. 28(5). p.1532-1547
Author
Organization
Abstract
Ileal epithelial cell apoptosis and the local microbiota modulate the effects of oxaliplatin against proximal colon cancer by modulating tumor immunosurveillance. Here, we identified an ileal immune profile associated with the prognosis of colon cancer and responses to chemotherapy. The whole immune ileal transcriptome was upregulated in poor-prognosis patients with proximal colon cancer, while the colonic immunity of healthy and neoplastic areas was downregulated (except for the Th17 fingerprint) in such patients. Similar observations were made across experimental models of implanted and spontaneous murine colon cancer, showing a relationship between carcinogenesis and ileal inflammation. Conversely, oxaliplatin-based chemotherapy could restore a favorable, attenuated ileal immune fingerprint in responders. These results suggest that chemotherapy inversely shapes the immune profile of the ileum-tumor axis, influencing clinical outcome.
Keywords
INTESTINAL MICROBIOTA, COLORECTAL-CANCER, PD-1 BLOCKADE, CELLS, TUMORS

Downloads

  • s41418-020-00684-w.pdf
    • full text (Published version)
    • |
    • open access
    • |
    • PDF
    • |
    • 4.35 MB

Citation

Please use this url to cite or link to this publication:

MLA
Picard, Marion, et al. “Ileal Immune Tonus Is a Prognosis Marker of Proximal Colon Cancer in Mice and Patients.” CELL DEATH AND DIFFERENTIATION, vol. 28, no. 5, 2021, pp. 1532–47, doi:10.1038/s41418-020-00684-w.
APA
Picard, M., Yonekura, S., Slowicka, K., Petta, I., Rauber, C., Routy, B., … Roberti, M. P. (2021). Ileal immune tonus is a prognosis marker of proximal colon cancer in mice and patients. CELL DEATH AND DIFFERENTIATION, 28(5), 1532–1547. https://doi.org/10.1038/s41418-020-00684-w
Chicago author-date
Picard, Marion, Satoru Yonekura, Karolina Slowicka, Ioanna Petta, Conrad Rauber, Bertrand Routy, Corentin Richard, et al. 2021. “Ileal Immune Tonus Is a Prognosis Marker of Proximal Colon Cancer in Mice and Patients.” CELL DEATH AND DIFFERENTIATION 28 (5): 1532–47. https://doi.org/10.1038/s41418-020-00684-w.
Chicago author-date (all authors)
Picard, Marion, Satoru Yonekura, Karolina Slowicka, Ioanna Petta, Conrad Rauber, Bertrand Routy, Corentin Richard, Valerio Iebba, Maryam Tidjani Alou, Sonia Becharef, Pierre Ly, Eugenie Pizzato, Christian H. K. Lehmann, Lukas Amon, Christophe Klein, Paule Opolon, Ivo Gomperts Boneca, Jean-Yves Scoazec, Antoine Hollebecque, David Malka, Francois Ghiringhelli, Diana Dudziak, Geert Berx, Lars Vereecke, Geert van Loo, Guido Kroemer, Laurence Zitvogel, and Maria Paula Roberti. 2021. “Ileal Immune Tonus Is a Prognosis Marker of Proximal Colon Cancer in Mice and Patients.” CELL DEATH AND DIFFERENTIATION 28 (5): 1532–1547. doi:10.1038/s41418-020-00684-w.
Vancouver
1.
Picard M, Yonekura S, Slowicka K, Petta I, Rauber C, Routy B, et al. Ileal immune tonus is a prognosis marker of proximal colon cancer in mice and patients. CELL DEATH AND DIFFERENTIATION. 2021;28(5):1532–47.
IEEE
[1]
M. Picard et al., “Ileal immune tonus is a prognosis marker of proximal colon cancer in mice and patients,” CELL DEATH AND DIFFERENTIATION, vol. 28, no. 5, pp. 1532–1547, 2021.
@article{8694830,
  abstract     = {{Ileal epithelial cell apoptosis and the local microbiota modulate the effects of oxaliplatin against proximal colon cancer by modulating tumor immunosurveillance. Here, we identified an ileal immune profile associated with the prognosis of colon cancer and responses to chemotherapy. The whole immune ileal transcriptome was upregulated in poor-prognosis patients with proximal colon cancer, while the colonic immunity of healthy and neoplastic areas was downregulated (except for the Th17 fingerprint) in such patients. Similar observations were made across experimental models of implanted and spontaneous murine colon cancer, showing a relationship between carcinogenesis and ileal inflammation. Conversely, oxaliplatin-based chemotherapy could restore a favorable, attenuated ileal immune fingerprint in responders. These results suggest that chemotherapy inversely shapes the immune profile of the ileum-tumor axis, influencing clinical outcome.}},
  author       = {{Picard, Marion and Yonekura, Satoru and Slowicka, Karolina and Petta, Ioanna and Rauber, Conrad and Routy, Bertrand and Richard, Corentin and Iebba, Valerio and Alou, Maryam Tidjani and Becharef, Sonia and Ly, Pierre and Pizzato, Eugenie and Lehmann, Christian H. K. and Amon, Lukas and Klein, Christophe and Opolon, Paule and Boneca, Ivo Gomperts and Scoazec, Jean-Yves and Hollebecque, Antoine and Malka, David and Ghiringhelli, Francois and Dudziak, Diana and Berx, Geert and Vereecke, Lars and van Loo, Geert and Kroemer, Guido and Zitvogel, Laurence and Roberti, Maria Paula}},
  issn         = {{1350-9047}},
  journal      = {{CELL DEATH AND DIFFERENTIATION}},
  keywords     = {{INTESTINAL MICROBIOTA,COLORECTAL-CANCER,PD-1 BLOCKADE,CELLS,TUMORS}},
  language     = {{eng}},
  number       = {{5}},
  pages        = {{1532--1547}},
  title        = {{Ileal immune tonus is a prognosis marker of proximal colon cancer in mice and patients}},
  url          = {{http://dx.doi.org/10.1038/s41418-020-00684-w}},
  volume       = {{28}},
  year         = {{2021}},
}

Altmetric
View in Altmetric
Web of Science
Times cited: